Thus, similar to previous studies in the same intermediate prostate cancer risk group, PSA and Gleason score are less likely to indicate a patient’s risk to progression than genetic profiling or 3D structural telomere analysis [1,5]. The gene discussed is KLK3; the disease is Familial prostate cancer.